<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DYRK1B Protein</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Dual-specificity Tyrosine-Phosphorylation Regulated Kinase 1B</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>DYRK1B</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>DYRK family (MAP kinase superfamily)</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Chromosome 19q13.32</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>64.7 kDa</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Serine/Threonine Kinase</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/fibrosis" style="color:#ef9a9a">Fibrosis</a>, <a href="/wiki/heart-failure" style="color:#ef9a9a">Heart Failure</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">7 edges</a></td>
</tr>
</table>
DYRK1B (Dual-specificity Tyrosine-Phosphorylation Regulated Kinase 1B) is a member of the dual-specificity tyrosine-regulated kinase (DYRK) family, which belongs to the larger MAP kinase superfamily. This serine/threonine kinase is encoded by the DYRK1B gene located on chromosome 19q13.32 and plays critical roles in cell cycle regulation, cell proliferation, differentiation, and metabolic homeostasis[@ariccacl2019].
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DYRK1B Protein</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Dual-specificity Tyrosine-Phosphorylation Regulated Kinase 1B</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>DYRK1B</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>DYRK family (MAP kinase superfamily)</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Chromosome 19q13.32</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>64.7 kDa</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Serine/Threonine Kinase</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/fibrosis" style="color:#ef9a9a">Fibrosis</a>, <a href="/wiki/heart-failure" style="color:#ef9a9a">Heart Failure</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">7 edges</a></td>
</tr>
</table>
DYRK1B (Dual-specificity Tyrosine-Phosphorylation Regulated Kinase 1B) is a member of the dual-specificity tyrosine-regulated kinase (DYRK) family, which belongs to the larger MAP kinase superfamily. This serine/threonine kinase is encoded by the DYRK1B gene located on chromosome 19q13.32 and plays critical roles in cell cycle regulation, cell proliferation, differentiation, and metabolic homeostasis[@ariccacl2019].
The DYRK family comprises five members in humans: DYRK1A, DYRK1B, DYRK2, DYRK3, and DYRK4. While DYRK1A has been extensively studied in the context of [Alzheimer's disease](/diseases/alzheimers-disease) and [Down syndrome](/diseases/down-syndrome), DYRK1B has emerged as an important regulator with distinct tissue distribution and functional properties[@rosenberger2017].
DYRK1B is predominantly expressed in skeletal muscle, heart, and to a lesser extent in brain tissue. Its expression pattern differs from DYRK1A, which is highly expressed in neural tissues. However, both kinases share overlapping substrates and can compensate for each other in certain cellular contexts, particularly during neuronal development and function[@iwata2019].
The DYRK1B gene spans approximately 18.5 kb and consists of 15 exons. The gene encodes a 601-amino acid protein with a calculated molecular weight of 64.7 kDa. The catalytic domain is located in the N-terminal region, while the C-terminal region contains regulatory domains involved in protein-protein interactions and subcellular localization[@ariccacl2019].
DYRK1B expression is highest in skeletal muscle and heart, with moderate expression in the pancreas, kidney, and liver. In the brain, DYRK1B is expressed in various regions including the hippocampus, cortex, and cerebellum, though at lower levels than DYRK1A. Recent studies have detected DYRK1B expression in neurons, astrocytes, and microglia, suggesting roles in neural cell function[@chen2021].
Expression patterns change during development and in response to various physiological and pathological conditions. In the developing brain, DYRK1B expression increases during neurogenesis and neuronal migration, indicating potential roles in brain development[@chen2021].
DYRK1B contains a highly conserved kinase domain that catalyzes the phosphorylation of serine and threonine residues on target proteins. Like other DYRK family members, DYRK1B exhibits dual-specificity, capable of phosphorylating tyrosine residues in vitro, though its primary physiological substrates are serine and threonine residues[@ariccacl2019].
The kinase domain consists of 11 subdomains typical of eukaryotic protein kinases, including the activation loop containing the autophosphorylation site. Autophosphorylation at Tyr-273 in the activation loop is essential for DYRK1B catalytic activity and represents a key regulatory mechanism[@taira2010].
DYRK1B activity is regulated through multiple mechanisms:
Autophosphorylation: DYRK1B undergoes intramolecular autophosphorylation at its activation loop tyrosine, converting the kinase from a low-activity to a high-activity state[@taira2010].
Alternative Splicing: Multiple splice variants of DYRK1B have been identified, including variants with altered kinase activity and subcellular localization.
Protein-Protein Interactions: DYRK1B interacts with various regulatory proteins including 14-3-3 proteins, which can modulate its activity and localization.
Post-translational Modifications: Phosphorylation by upstream kinases and ubiquitination contribute to DYRK1B regulation.
DYRK1B plays important roles in cell cycle progression through phosphorylation of multiple substrates[@taira2010]:
G1/S Transition: DYRK1B phosphorylates and inhibits the activity of cyclin-dependent kinase inhibitors p21^Cip1^ and p27^Kip1^, promoting cell cycle progression from G1 to S phase.
S Phase Entry: DYRK1B interacts with the replication licensing complex and regulates DNA replication initiation.
G2/M Transition: DYRK1B phosphorylates proteins involved in mitotic entry and spindle assembly.
The regulation of cell cycle proteins by DYRK1B makes it an important regulator of cell proliferation, with implications for both normal development and cancer[@ariccacl2019].
In neuronal systems, DYRK1B contributes to neurodevelopment through several mechanisms[@teodorczyk2015]:
Neuronal Progenitor Proliferation: DYRK1B regulates the proliferation of neural progenitor cells during brain development.
Neuronal Differentiation: DYRK1B promotes neuronal differentiation by phosphorylating transcription factors involved in neuronal gene expression.
Synapse Formation: Emerging evidence suggests roles for DYRK1B in synaptic development and function.
DYRK1B has been implicated in metabolic pathways, particularly in muscle and liver tissues[@yang2019]:
Gluconeogenesis: DYRK1B phosphorylates and regulates transcription factors controlling gluconeogenic gene expression.
Lipid Metabolism: DYRK1B affects lipid synthesis and storage pathways.
Insulin Signaling: Studies suggest interactions between DYRK1B and insulin signaling pathways.
While less studied than DYRK1A, DYRK1B has been implicated in Alzheimer's disease pathogenesis through several mechanisms[@hoo2022]:
Tau Phosphorylation: Both DYRK1A and DYRK1B can phosphorylate tau protein at multiple sites. DYRK1B-mediated tau phosphorylation at Ser-202, Thr-205, and other sites contributes to tau aggregation and neurofibrillary tangle formation. Studies in cell models and animal models have demonstrated that DYRK1B can phosphorylate tau and promote its aggregation into insoluble aggregates[@liu2020].
Amyloid-beta Toxicity: Research has shown that DYRK1B expression is altered in response to amyloid-beta exposure. Voronova et al. demonstrated that DYRK1B modulates amyloid-beta-induced toxicity in neuronal cells, suggesting a protective or adaptive role[@voronova2020].
Gene Association Studies: Polymorphisms in the DYRK1B gene have been associated with increased Alzheimer's disease risk in some populations, though findings are not consistent across all studies[@wong2021].
DYRK1B has been studied in the context of [Parkinson's disease](/diseases/parkinsons-disease) with emerging evidence for involvement in dopaminergic neuron survival[@kelley2020]:
Dopaminergic Neuron Function: Studies in dopaminergic cell models suggest that DYRK1B may regulate neuron survival and stress responses.
Alpha-synuclein: While direct interactions between DYRK1B and alpha-synuclein are less characterized, the kinase may influence pathways relevant to alpha-synuclein aggregation and toxicity.
Compensation for DYRK1A: In dopaminergic neurons, DYRK1B may compensate for DYRK1A loss or dysfunction, suggesting functional redundancy in certain neuronal populations[@iwata2019].
DYRK1B has been linked to autophagy and protein clearance pathways that are disrupted in neurodegenerative diseases[@abdelgawad2019]:
Autophagy Regulation: DYRK1B phosphorylates proteins involved in autophagosome formation and lysosomal fusion.
Proteostasis: Through effects on protein clearance pathways, DYRK1B may influence the accumulation of misfolded proteins in neurodegenerative diseases.
Recent research has revealed roles for DYRK1B in mitochondrial dynamics and function[@lee2018]:
Mitochondrial Dynamics: DYRK1B regulates mitochondrial fission and fusion processes.
Energy Metabolism: By affecting mitochondrial function, DYRK1B influences cellular energy metabolism, which is critical for neuronal survival.
DYRK1B is frequently overexpressed in various cancers and is considered a potential therapeutic target[@rodriguez2018]:
Oncogenic Functions: DYRK1B promotes cancer cell proliferation and survival through cell cycle regulation and anti-apoptotic effects.
Therapeutic Targeting: Small molecule inhibitors of DYRK1B have been developed and are being evaluated for cancer therapy[@becker2018][@fatemipour2022].
Mutations in DYRK1B have been associated with intellectual disability and developmental delay, though less frequently than DYRK1A mutations[@eishima2021][@muller2019]:
Developmental Delays: Loss-of-function mutations cause variable developmental phenotypes.
Phenotype Overlap: There is phenotypic overlap with DYRK1A-related disorders, suggesting related mechanisms.
DYRK1B has been implicated in metabolic syndrome and diabetes[@yang2019]:
Insulin Resistance: Studies link DYRK1B to insulin signaling and glucose homeostasis.
Obesity: Some genetic studies suggest associations between DYRK1B variants and obesity risk.
DYRK1B has emerged as a potential drug target for several conditions:
Cancer Therapy: Selective DYRK1B inhibitors are being developed for cancer treatment. These inhibitors induce cell cycle arrest and apoptosis in cancer cells expressing high levels of DYRK1B[@becker2018][@fatemipour2022].
Neurodegenerative Diseases: Modulating DYRK1B activity may have therapeutic potential in Alzheimer's and Parkinson's diseases. However, given the complex roles of DYRK1B and its functional redundancy with DYRK1A, careful consideration of beneficial versus harmful effects is necessary.
DYRK1B expression in peripheral tissues is being investigated as a potential biomarker:
Disease Biomarkers: DYRK1B expression patterns may serve as biomarkers for disease progression or treatment response.
DYRK1B interacts with multiple proteins involved in various cellular processes[@ariccacl2019]:
DYRK1B participates in several signaling cascades:
MAPK Pathway: As a member of the MAP kinase superfamily, DYRK1B relates to MAPK signaling pathways.
PI3K/AKT Pathway: Cross-talk with survival and growth factor signaling.
Wnt/β-catenin Pathway: Interactions with Wnt signaling components.
Research on DYRK1B employs various methodologies:
Molecular Biology: Gene cloning, mutagenesis, and expression analysis
Biochemistry: Kinase assays, substrate identification, and protein interaction studies
Cell Biology: Cell culture models, siRNA/shRNA knockdown, and overexpression studies
Animal Models: Transgenic and knockout mice for in vivo studies
Clinical Studies: Genetic association studies and biomarker development
Key questions remain about DYRK1B function:
Areas of active investigation include: